I think we would all have liked to get more for the company, but reality is that only other option was another CR shortly to just supply cash flow/salaries etc, creating further SP depreciation and dilution. They are no where near being cash flow positive, which might have allowed more time. Suspect big shareholders have had enough and looking to lock in value, albeit less than initially hoped for. Big companies know this also so not prepared to pay premium. Other risk is that if waiting too long for higher bidder, the technology is superseded in fast changing world of genomics, and becomes worthless. At least this puts a floor under the share price, and maybe just maybe another bidder will emerge. If not, then proves its not worth more than $25mill. So all in all not as bad a deal as being made out IMO. Happy enough and will move on.
RHS Price at posting:
26.5¢ Sentiment: Hold Disclosure: Held
